Treatment of Advanced-Stage Follicular Lymphoma (Stage III–IV) When GELF Criteria Are Met
This protocol applies to patients with follicular lymphoma that has reached advanced stage (III–IV), is symptomatic, and meets the GELF criteria indicating that treatment — rather than watchful waiting — is required.
Clinical scenario
All patients with advanced-stage follicular lymphoma should be assessed against the GELF criteria. When those criteria are fulfilled — indicating significant disease burden or symptomatic involvement — active systemic treatment is indicated. Failure to meet GELF criteria supports an observation strategy instead.
Treatment approach — partial overview
The standard approach combines an anti-CD20 monoclonal antibody with a chemotherapy backbone. The specific chemotherapy partner is selected on the basis of patient factors and clinician judgement. The complete regimen, supportive care requirements, and considerations for maintenance therapy are set out in full in the structured protocol.
References
- All people with advanced stage FL should be assessed against the GELF criteria to ascertain if they require treatment.
- Based on these data, it is clear that an anti-CD20 monoclonal antibody should be added to chemotherapy in the treatment of advanced stage, symptomatic FL but there is less consensus as to which chemotherapy regimen it should be paired with.
- Offer rituximab or obinutuzumab with chemotherapy for people who require treatment. The chemotherapy with which the antibody should be paired (e.g. bendamustine, chlorambucil, CHOP, CVP) is dependent on patient factors and clinician choice.
View source ↗